Markers study for treatment response in pancreatic cancer
Part of Cancer clinical trials.
This study looks at tumor “markers” (tests on cancer tissue or related information) to understand how you may respond to first-line treatment for pancreatic cancer. Your results may help doctors better predict which treatments work best for different people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreas cancer (pancreatic adenocarcinoma) confirmed by pathology/biopsy.
- Your cancer is at resectable, borderline, locally advanced, initially metastatic, or recurrent after surgery.
- You were diagnosed between Jan 1, 2003 and Dec 31, 2030.
- You plan to start first treatment (chemotherapy and/or radiation and/or a clinical trial).
- You are age 18 or older and can sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at advanced or metastatic pancreatic cancer patients and uses stored tumor tissue to learn what may predict treatment outcomes. You may be able to join if you have had limited prior chemotherapy and can provide an archived tissue sample.
This study looks for new markers in the blood or tissue of people with a pancreatic mass that might be cancer. It uses samples from a routine biopsy or surgery to help doctors learn more about the disease.
This study looks at “biomarkers” (test signals in tissue or blood) in people with pancreatic cancer. It may help researchers understand the disease better and find ways to predict or track it.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This study looks at “tumor regulatory molecules,” which are substances that may be released by cancer, to improve early pancreatic cancer detection. You may join if you have early, localized pancreatic cancer that can be treated with surgery, or certain pancreatic cysts/fluid collections where doctors are investigating further.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.